Work Here?
Overview
Teiko.bio maps immune profiles to guide immunotherapy and personalized medicine by analyzing interactions between immune and tumor cells to produce actionable data for biopharma clients. Its core offering, the customizable TokuProfile panel with 35+ immune markers, generates an immune fingerprint for each patient to identify predictive markers and monitor treatment impact. The company earns revenue from selling panels and data-analysis services, providing end-to-end immune profiling tailored to drug development and patient stratification. Its goal is to help biopharma companies develop more effective therapies and improve patient outcomes through precise immune data.
About Teiko
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Salt Lake City, Utah
Founded
2020
People at Teiko
People at Teiko who can refer or advise you
Simplify's Take
What believers are saying
- Teiko secured $11.6M in oversubscribed Series A funding in 2024 to advance its immune profiling platform and predictive algorithms.
- Zumutor Biologics selected Teiko in 2025 for a custom 42-marker panel to develop its NK checkpoint therapeutic candidate ZM008.
- Teiko launched a spectral flow TokuKit in 2025, analyzing 146 immune populations with month+ stability in fixed whole blood.
What critics are saying
- Direct competition from Cellipont Bioservices and Cellevolve Bio with established CLIA platforms threatens Teiko's market share within 12–18 months.
- Teiko's $11.6M Series A funding is insufficient to sustain R&D and scale against well-funded competitors, risking cash exhaustion in 9–15 months.
- Failure to secure a pivotal partnership with a top-tier pharma firm like Moderna by 2027 could render Teiko's niche model commercially irrelevant.
What makes Teiko unique
- Teiko uses mass cytometry to profile over 1 trillion unique immune phenotypes, surpassing flow cytometry by 1 billion-fold.
- The company offers a CLIA-certified end-to-end solution analyzing 750+ immune cell populations with single-digit coefficient of variations.
- Teiko's TokuProfile panel includes 33+ markers with 10 open channels for customization, enabling precise immune fingerprinting for clinical trials.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 5%2 year growth
↓ -4%Teiko, Inc. is excited to announce the launch of "Download All", a new feature designed to solve the problem of manually accessing gating plots.
Teiko, Inc. is announcing a new upgrade to its AI-powered "Pocket Immunologist" within your dashboards on app.teiko.bio.
San Francisco, CA - July 31, 2025 - Teiko, Inc. has announced the launch of Pocket Immunologist, an AI-powered tool designed to help you quickly interpret high-dimensional cytometry data from your clinical trials.
As part of this study on CD38[+] T cell exhaustion and ICB resistance, Teiko partnered with MGH to analyze 86 melanoma patient blood samples via mass cytometry, uncovering CD38[+] T cell signatures tied to ICB resistance.
Teiko, Inc. has officially released a major upgrade to the Teiko Dashboard: Samples Overview.
Teiko is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Teiko
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
Salt Lake City, Utah
Founded
2020
Teiko is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today